KMD Bioscience

Executive Summary

KMD Bioscience is a Chinese biotechnology company headquartered in Tianjin, specializing in antibody discovery and proteomics services. Founded in 2014, the company offers comprehensive CRO services including nanobody (VHH) discovery, aptamer screening, peptide library construction, and antibody development platforms. Their expertise spans therapeutic antibody development, diagnostic raw materials, and veterinary applications, positioning them as a versatile partner for both human and animal health markets. With a team of 50-200 employees, KMD supports clients from early discovery through preclinical development, leveraging its proprietary platforms to accelerate drug and diagnostic development.

Upcoming Catalysts (preview)

• Q2 2026Launch of Next-Generation Nanobody Discovery Platform80% success
• Q3 2026Strategic Partnership with Global Pharma for Veterinary Antibodies60% success
• Q4 2026Series B Funding Round Completion70% success